Molecular diagnosis and outcome prediction in diffuse large B-cell lymphoma and other subtypes of lymphoma.
Molecular diagnosis and outcome prediction in diffuse large B-cell lymphoma and other subtypes of lymphoma.
复制标题
DOI：
10.3816/clm.2004.n.006
复制
发表时间：
2004-06
期刊：
影响因子：
--
通讯作者：
K. Dybkaer;J. Iqbal;Guimei Zhou;W. Chan
中科院分区：
文献类型：
--
作者：
K. Dybkaer;J. Iqbal;Guimei Zhou;W. Chan
恶性淋巴瘤的分类和特征在于它们的形态，免疫表型和遗传畸变，以帮助建立诊断。使用微阵列技术能够同时测定数千个基因的表达水平，为改善疾病分类提供了额外的强大工具。在这篇综述中，弥漫性大B细胞淋巴瘤（DLBCL），原发性纵隔大B细胞淋巴瘤，套细胞淋巴瘤（MCL），滤泡性淋巴瘤的最新研究突出，并对这些疾病的分子诊断基因表达谱的影响进行了讨论。基于微阵列生成的基因表达谱，构建DLBCL和MCL的结局预测因子。在DLBCL和MCL中，诊断时有限数量基因的特异性表达模式与总生存率相关。这些预后预测因子可能最终导致淋巴瘤的风险调整治疗。特异性治疗靶点也可能随着对不同淋巴瘤的分子特征的深入了解而出现，从而说明基因表达谱不仅对改善诊断和分类而且对产生预后指标和治疗靶点的有用性。
Lymphoid malignancies are grouped and characterized by their morphology, immunophenotype, and genetic aberrations to help establish a diagnosis. Use of microarray technology enables the simultaneous determination of expression levels for thousands of genes, providing an additional powerful tool for improving disease classification. In this review, recent studies of diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, mantle cell lymphoma (MCL), and follicular lymphoma are highlighted, and the impact of gene expression profiling on the molecular diagnosis of these diseases is discussed. Based on microarray-generated gene expression profiles, outcome predictors were constructed for DLBCL and MCL. Specific expression patterns of a limited number of genes at the time of diagnosis were linked to overall survival in DLBCL and MCL. Such predictors of prognosis may eventually lead to risk-adjusted treatment of lymphomas. Specific therapeutic targets may also emerge with increased insight into the molecular features of the different lymphomas, thus illustrating the usefulness of gene expression profiling not only to improve diagnosis and classification but also to generate prognostic indicators and targets for therapy.